Ligand validation:6SU4

OLC: (2R)-2,3-dihydroxypropyl (9Z)-octadec-9-enoate

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6SU4_OLC_A_702	25%	56%	0.16	0.792	0.89	0.83	1	1	3	0	100%	1
6SU4_OLC_X_605	22%	52%	0.161	0.779	0.96	0.89	1	1	0	0	96%	0.96
6SU4_OLC_X_604	18%	54%	0.159	0.751	0.93	0.87	1	1	0	0	96%	0.96
6SU4_OLC_A_703	14%	55%	0.177	0.722	0.93	0.82	1	1	0	0	100%	1
6SU3_OLC_A_804	33%	43%	0.199	0.943	1.01	1.18	1	2	1	0	64%	0.64
7Z0C_OLC_A_803	63%	52%	0.097	0.892	0.82	1.04	1	2	2	0	100%	1
4N6H_OLC_A_1222	63%	56%	0.117	0.932	0.81	0.87	1	1	0	0	88%	0.88
5IU4_OLC_A_2429	61%	59%	0.136	0.926	0.8	0.78	2	1	1	0	100%	1
6G7H_OLC_A_310	61%	92%	0.117	0.905	0.26	0.26	-	-	0	0	100%	1
7B0O_OLC_A_302	59%	55%	0.146	0.929	0.68	1.06	1	1	2	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.